Research Article
Research Progress and Real-World Research Perspectives of Immunity-Based Combination Regimens for Hepatocellular Carcinoma in the Chinese Population
Issue:
Volume 15, Issue 5, October 2026
Pages:
69-74
Received:
9 September 2026
Accepted:
4 October 2026
Published:
10 November 2026
Abstract: China bears the world's heaviest disease burden of hepatocellular carcinoma (HCC), with hepatitis B virus (HBV) infection as the predominant aetiology. Most patients are diagnosed at intermediate-to-advanced stages, achieving only limited benefit with conventional systemic therapy. Combination therapies centring on programmed death-1 (PD-1)/programmed death ligand-1(PD-L1) immune checkpoint inhibitors have reshaped the diagnostic and therapeutic landscape of HCC, establishing four mainstream modalities: immunotherapy combined with anti-angiogenic targeted agents, dual immunotherapy, immunotherapy plus locoregional therapy, and perioperative targeted-immunotherapy with comprehensive management. While phase III clinical trials and updated domestic guidelines have confirmed that these combination regimens significantly improve objective response rates and prolong overall survival, the stringent eligibility criteria of randomised controlled trials (RCTs) limit their generalisability. These criteria make it difficult to reflect real-world treatment outcomes in Chinese patients, who frequently present with coexisting liver cirrhosis, hepatic impairment, and multiple comorbidities—resulting in a notable gap in stratified, real-world evidence generated from local populations. This review systematically summarises the mechanisms of action, clinical evidence, and evolving guideline recommendations for immune-based combinations in Chinese patients with HCC, and analyses current bottlenecks in clinical research. Based on the design of a national multicentre real-world registry study, we further discuss the value of real-world research for optimising individualised immunotherapy for HCC in China, so as to provide evidence-based references for clinical practice and scientific exploration.
Abstract: China bears the world's heaviest disease burden of hepatocellular carcinoma (HCC), with hepatitis B virus (HBV) infection as the predominant aetiology. Most patients are diagnosed at intermediate-to-advanced stages, achieving only limited benefit with conventional systemic therapy. Combination therapies centring on programmed death-1 (PD-1)/program...
Show More
Research Article
A Diagnostic Challenge: Giant Cell Arteritis Presenting as Fever of Unknown Origin
Vishnu Vandana Dubakula*,
Sai Deepak Muthyala,
Megan Kudlak,
Sameera Vohra,
Tauqeer Yousuf
Issue:
Volume 15, Issue 5, October 2026
Pages:
75-80
Received:
25 August 2026
Accepted:
19 October 2026
Published:
16 November 2026
DOI:
10.11648/j.cmr.20261505.12
Downloads:
Views:
Abstract: Background: Fever of unknown origin (FUO) in elderly patients presents a major diagnostic challenge due to its broad differential diagnosis and frequently nonspecific clinical manifestations. Although infections, malignancies, and connective tissue diseases are common etiologies, atypical presentations of vasculitis remain an underrecognized cause of persistent fever. Giant cell arteritis classically presents with headache, jaw claudication, and visual symptoms; however, a subset of patients may present solely with constitutional symptoms, leading to delayed diagnosis and increased risk of irreversible complications. We report a rare case of biopsy-confirmed non-giant-cell temporal arteritis presenting as prolonged FUO without cranial symptoms despite markedly elevated inflammatory markers and an extensive negative infectious and malignancy evaluation. Case Report: An 85-year-old female presented with several weeks of low-grade fever and fatigue, without associated headache, jaw claudication, or visual deficits. Initial laboratory workup was pertinent for leukocytosis and markedly elevated inflammatory markers (ESR/CRP). Extensive workup, including blood cultures, urinalysis, chest and abdominal CT imaging, transthoracic echocardiography, tuberculosis testing, and autoimmune serologies, was unrevealing. Multiple courses of empiric broad-spectrum antibiotics provided no symptom relief. Due to persistent elevation of ESR and CRP, and in the absence of an identifiable source, an autoimmune etiology such as temporal arteritis was higher on the differential. A temporal artery biopsy was subsequently performed and showed features consistent with non-giant cell arteritis. High-dose corticosteroid therapy was initiated, leading to rapid resolution of her fever and constitutional symptoms, as well as normalization of white blood cell count. Conclusion: This case highlights the importance of considering temporal arteritis in elderly patients with persistent fever of unknown origin, markedly elevated ESR and CRP, and unrevealing infectious or malignant workup, even in the absence of classic cranial manifestations. It also emphasizes the diagnostic value of temporal artery biopsy in atypical presentations and expands the limited literature describing biopsy-confirmed non-giant-cell arteritis presenting primarily as FUO. Key clinical message: Non-giant cell temporal arteritis should be considered in elderly patients with fever of unknown origin and markedly elevated inflammatory markers even in the absence of classic cranial symptoms. Early recognition and prompt corticosteroid therapy can lead to rapid clinical improvement and prevent irreversible complications such as vision loss and vascular ischemia.
Abstract: Background: Fever of unknown origin (FUO) in elderly patients presents a major diagnostic challenge due to its broad differential diagnosis and frequently nonspecific clinical manifestations. Although infections, malignancies, and connective tissue diseases are common etiologies, atypical presentations of vasculitis remain an underrecognized cause ...
Show More